Trial Profile

Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes - the Role of Glucagon

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adomeglivant (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

01 Oct 2022 Results assessing effect of glucagon receptor antagonism on Gastrointestinal-mediated glucose disposal, incretin effect and glucose excursions in patients with T2D and controls without diabetes published in the European Journal of Endocrinology
15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
24 Oct 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com